The exit was completed in 2026 through two stake sale transactions by BC Investments IV. On June 9, 2026, the entity sold 36 lakh shares of Emcure Pharmaceuticals via a block deal at ₹1,700 per share, amounting to ₹612 crore.
ALSO READ | Emcure Pharma Q2 | Profit rises 25% to ₹243 crore, revenue up 13% YoYEarlier, on April 30, 2026, Bain Capital divested nearly a 1% stake in the company through open market transactions. BC Investments IV sold 18 lakh shares, representing a 0.95% stake, for over ₹289 crore.
Fourth Quarter Results
Net profit for the quarter rose 29% year-on-year to ₹243 crore from ₹189 crore. Revenue increased 16.7% to ₹2,469.7 crore compared to ₹2,116.2 crore in the year-ago period, reflecting healthy traction across key markets. EBITDA grew 19.2% to ₹479.5 crore, while margins improved marginally to 19.4% from 19% a year earlier.The company’s international business remained the key growth driver, with sales rising 25.7% YoY to ₹1,493 crore, supported by base business ramp-up and new product launches. Domestic sales came in at ₹977 crore, up 5.2% YoY, impacted by softer performance in the Zuventus portfolio and organisational restructuring.
ALSO READ | Emcure Pharma receives 7 US FDA observations for Sanand formulations facility in Gujarat
The board recommended a final dividend of ₹3.60 per share for FY26, subject to shareholder approval. It also approved the re-appointment of Dr Mukund Gurjar as Whole-time Director for one year from August 2026, and Satish Mehta as Managing Director for five years from April 2027.
Pune-based firm Emcure Pharmaceuticals is engaged in developing, manufacturing, and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
Shares of Emcure Pharmaceuticals Ltd ended at ₹1,881.90, up by ₹43.75, or 2.38%, on the BSE.
ALSO READ | Emcure Pharma cuts Poviztra starting dose price by 55% to boost patient access
